SEATTLE MIDLIFE WOMEN S HEALTH STUDY OVERVIEW

Similar documents
The menopausal transition usually has three parts:

WOMENCARE A Healthy Woman is a Powerful Woman (407) Hormone Therapy

Neuroendocrine Evaluation

Bio-Identical Hormone FAQ s

patient education Fact Sheet PFS003: Hormone Therapy APRIL 2015

Shira Miller, M.D. Los Angeles, CA The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library

Now that your Doctor has prescribed Livial for you

Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions

DEPRESSION DURING THE TRANSITION TO MENOPAUSE: A Guide for Patients and Families

From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels. Christine Day, RN, MS, CNS-BC Lake Superior College

Smoking and Age of Menopause. Women who smoke experience menopause an average of 2 years earlier than women who do not smoke.

(212)

Understanding Your Risk of Ovarian Cancer

WOMENCARE A Healthy Woman is a Powerful Woman (407) Endometriosis

Hormone Replacement Therapy For Women

Hormone. Replacement. Therapy. Information leaflet. This information is also available on request in other formats by phoning

The Menopause and Subtotal Hysterectomy

Menstruation and the Menstrual Cycle

I will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too?

Lakeview Endocrinology and Diabetes Consultants N Halsted St C-1. Chicago IL P: F:

Depressive disorders among older residents in a Chinese rural community. Risk for Depression by Age and Sex. Risk for Depression by Age and Sex

WOMENCARE A Healthy Woman is a Powerful Woman (407) Birth Control Pills

Are You at Risk for Ovarian Cancer?

progestog progestogen stogen-only pill progestogen progestogen-only pill he progestogen-only pill progestogen-onl progestogen-o the progestogenonly

WOMEN AND ADDICTION RECOVERY & HORMONAL SHIFTS

Depression in the Menopause and Perimenopause

Female Reproductive System. Unit 8 Lesson 2 Continued

Menopause: should I take HRT?

Obesity and the Menopause. Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology

Menopause and Hormone Replacement Therapy

High Blood Pressure. What Is Blood Pressure?

Kantar Health, New York, NY 2 Pfizer Inc, New York, NY. Experiencing depression. Not experiencing depression

injections injections injections injections injections injection injections injections injections tions njections injections injections injections

Alternatives to hormone replacement therapy for symptoms of the menopause

About the Uterus. Hysterectomy may be done to treat conditions that affect the uterus. Some reasons a hysterectomy may be needed include:

MENOPAUSE WOMAN'S TEST (Assessment of hormone balance)

Helping you manage symptoms and side effects associated with metastatic breast cancer treatment

Women s Reproductive Health and Traumatic Brain Injury

What is the menopause and what are the symptoms?

Polycystic Ovarian Syndrome

Abnormal Uterine Bleeding FAQ Sheet

Testosterone Therapy for Women

Remember: Not everyone experiences these persistent and late side effects.

Abnormal Uterine Bleeding

Combination Birth Control Pills - FAQ

Risk Management Plan

Hormone Therapy with Tamoxifen

implant contraceptiv contraceptive contraceptive raceptiv contraceptive implant contraceptive contraceptive ontraceptive implant ontraceptive im

Menopause. Weight Loss. A Special Report on Weight Gain During Menopause. contact us. FROM THE DESK OF: Carolyn J. Cederquist, M.D. Dr.

Getting Pregnant: The Natural Approach Revealing the Secrets to Increase Your Fertility

Managing Menopause. Signs

Understanding Fertility

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology (Patient Label)

Dr. Friedman s Guide to Estrogen Replacement

Postpartum Depression and Post-Traumatic Stress Disorder

What Are Fertility Awareness Methods?

Menstruation and the Menstrual Cycle

Reduce Your Risk of Breast Cancer

Clinical Trials Network

From this site: /vitalzym/fibroid_tumors.html Uterine Fibroid Tumors

Chickenpox and Shingles Vaccines

Page The production of monoploid cells by spermatogenesis occurs in (1) zygotes (3) ovaries (2) testes (4) meristems

COULD IT BE LOW TESTOSTERONE?

Male menopausal symptoms during and after cancer treatment

Aging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone

Polycystic ovary syndrome: what it means for your long-term health

X-Plain Chemotherapy for Breast Cancer - Adriamycin, Cytoxan, and Tamoxifen Reference Summary

HPV is very common and usually clears up on its own

Patient information. Goserelin Zoladex Breast Services Directorate PIF 1005 V3

Polycystic Ovarian Syndrome (PCOS)

Reproductive System & Development: Practice Questions #1

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Sykes D, Out H J, Palmer S J, van Loon J

Pellet Implant FAQ Provided By: Rebecca Glaser, MD, FACS

Ovarian Cyst. Homoeopathy Clinic. Introduction. Types of Ovarian Cysts. Contents. Case Reports. 21 August 2002

Coping With Stress and Anxiety

Male Patient Questionnaire & History

Abigail R. Proffer, M.D. October 4, 2013

MEDICATION GUIDE ACTOPLUS MET (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets

Hormone replacement therapy:

Summa Health System. A Woman s Guide to Hysterectomy

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE

11 Serious and life-threatening side effects can occur while taking EVISTA. These include 12 blood clots and dying from stroke:

Hull & East Riding Prescribing Committee

Endocrinology of the Female Reproductive Axis

BREAST CANCER. How to spot the signs and symptoms and reduce your risk. cruk.org

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Glossary. amenorrhea, primary - from the beginning and lifelong; menstruation never begins at puberty.

Transcription:

SEATTLE MIDLIFE WOMEN S HEALTH STUDY OVERVIEW The Seattle Midlife Women s Health Study (SMWHS) studied the natural menopausal transition in a population-based sample from 1990 to 2006. The primary focus of SMWHS throughout the 17 years was on symptoms, hormones, stress and stages of the menopausal transition. To find eligible women to participate in the study, 11,222 households were contacted by phone. 508 women between the ages of 35 and 55 were recruited between 1990 and 1992. After the initial interview 390 (77%) agreed to provide data annually by questionnaire, daily menstrual calendar, or health diary. At the end of 5 years, 242 of 300 women who were still eligible to participate(81%), agreed to continue in the study with 176 of these (73%) providing 3-day diaries or first morning urine specimens. Between 2000 and 2002, 174 women provided a buccal cell smear for genotyping. Participation in SMWHS 1990-2006 Still in study as of Dec. 31, 2006 Lost to follow-up Ineligible Too busy Number Percent (%) 64 12.6 153 30.1 121 23.8 73 14.4 Personal/family reason making it difficult to participate 26 5.1 Moved, unwilling to continue Lost interest 14 2.8 57 11.2 Total 508 100.0

Publications referred to with findings are listed separately. Under review means that the article is undergoing review for potential publication. In progress means that articles are being written. Menopausal Transition (MT) Midlife SELECTED FINDINGS The MT can be divided into specific stages (Mitchell, Woods & Mariella, 2000): o Early stage - cycles are still regular but length of periods, amount of flow or cycle length has changed o Middle stage - cycles become irregular. Consecutive cycles are 7 or more days different from each other. o Late stage - periods are skipped; there are 60 or more days between the start of consecutive periods. The length of a period, time between periods and amount of bleeding increase as women age. The length of a period and amount of bleeding increases steadily across the MT stages (In progress). On average women enter Middle stage at age 46.1 and stay in the stage for an average of 2.8 years. On average, women enter Late stage at age 49.1 and stay in this stage for an average of 2.6 years. The average age for the final menstrual period (start of postmenopause) is 51.6 years (In progress). Women themselves define MT as the cessation of periods, the end of reproductive ability, a time of hormonal changes, change of life, changing body and emotions and an aging process. Very few women define the MT as a time of symptom or disease risk (Woods & Mitchell, 1999). Women describe midlife as a time of many transitions, of getting older, of changing bodies, outlooks and relationships. Personal achievements and employment are central to the lives of midlife women in this study (Woods &Mitchell, 1997). After publication of Women s Health Initiative findings (2002) linking hormone therapy (HT)with increased risk of breast cancer, stroke, heart attacks and other health problems the percent of women taking hormones during the MT decreased from 49% in 1999 to 35% in 2003. Reasons to not take HT increased between 1999 and 2003 as follows: concerns raised by news reports, from 20% to 66%; imbalance between benefits and risks, from 39% to 86%; worry about cancer from 37% to 73%, concerns about side effects from 35% to 68%, and viewing menopause as natural from 29% to 59%. Advice against taking estrogen increased from 13% to 36% (Smith-DiJulio, Mitchell, Woods, 2005).

Hormonal Changes FSH (follicle-stimulating hormone, the driver of hormone secretion from the ovary) rises as women go from Middle to Late MT stage and to early postmenopause (PM) (Mitchell, Woods & Mariella, 2003). Estrone levels do not drop until at least one year after the beginning of Late stage (Estrone is one of the 3 estrogens secreted by the ovary and the one we measured.) (In progress). Cortisol (a stress hormone) increases during Late stage. Women with increased cortisol levels have more severe hot flashes than those without a cortisol increase. Other factors such as age, body mass index, FSH, estrone, exercise level, depressed mood, sleep disruption or stress level do not differentiate between women with high or low cortisol levels (Woods, Carr, Tao, et al., 2006). Symptoms At the beginning of the study 58% of the women said they had PMS (premenstrual syndrome) at some point in their lives; half of those with a moderate or extreme level. Women with PMS have more life stress than women without PMS. PMS is more likely among women with 12 years or less education; younger women, women who can tell when they ovulate, and those whose mothers had similar symptoms. There is no difference between women with and without PMS on number of cigarettes smoked, alcoholic drinks consumed or amount of exercise (In progress). Women experience the following: depressed mood, hot flashes, decreased sexual desire, vaginal dryness, forgetfulness, difficulty concentrating, awakening during the night or early morning awakening, not all of which can be attributed to the MT (Mitchell & Woods, 1996). Hot flashes are related to a rise in FSH and a drop in estrone during the MT and early PM (Woods, Smith-DiJulio, Percival, et al., under review). Hot flash experiences across the MT are highly variable. Hormone therapy relieves hot flashes with 75% of women reporting fewer and less severe hot flashes (Smith-DiJulio, Mitchell, Woods, 2005), but this effect is not predictable, ie, not all women can count on relief of hot flashes with hormones use (In progress). Decreased sexual desire is associated with a decline in estrone levels. Vaginal dryness is related to a rise in FSH and a decline in testosterone during the MT and early PM (Woods, Smith-DiJulio, Percival, et al., under review). Forgetfulness increases along with FSH levels. Difficulty concentrating is associated with lower levels of testosterone (Woods, Smith-DiJulio, Percival, et al., under review).

Depressed mood is not directly associated with hot flashes, but is associated with early morning awakening and awakening during the night. Early morning awakening and awakening during the night are directly associated with hot flashes (Woods, Smith-DiJulio, Percival, et al., under review). Women with a consistently depressed mood are more likely to have hot flashes, stress, history of premenstrual syndrome and postpartum blues than other women (Woods & Mitchell, 1996). Depressed mood increases slightly with age, hot flashes, and number of life events; more substantially with use of antidepressants (In progress). Most women experience the MT without a high level of depressed mood. A small group of women have their mood worsen. Another small group has their mood improve (Woods, Mariella & Mitchell, 2006). The occurrence of depressed mood is highly variable. It increases with aging, hot flash activity, use of antidepressants, stress and Late transition stage (In progress). About 72% of women report problems remembering names at least some of the time. About 50% have a problem remembering where they put things, recent phone numbers, things others told them (or they told others), keeping up correspondence and forgetting what they were doing. However, none of these events are considered a serious problem (Woods, Mitchell, & Adams, 2000). Many types of problems with memory are related to lower ratings of health and depressed mood. Problems with current memory and remembering past events are associated with higher levels of reported stress, which women attribute to the burden of meeting multiple role demands (Woods, Mitchell, & Adams, 2000). Women in the Early and Middle stages of the MT and those who use hormones have more problems with memory than women in Late stage (Woods, Mitchell, & Adams, 2000). Genetic Influences Women with a specific genetic variations have more severe and frequent hot flashes during the Middle and Late MT stages and PM and have higher estrone levels during Middle and Late stages (Woods, Mitchell, Tao, et. al., 2006). Genetic differences influence the age of first menstruation, the age of entry into Middle and Late stage and age at final menstrual period. How long a woman is in Middle or Late stage is not influenced by genetic variation (Under review).

INTERNATIONAL COLLABORATION The data you gave us has been used as part of an international collaboration to assess ways to identify MT stages and to determine whether to support adoption of specific hormonal criteria to define the MT. This collaboration recommends the adoption of 7 day difference in repeated consecutive cycle lengths as the method to define onset of irregularity and the start of the MT. Also recommended is the use of at least 60 days of no bleeding as the approach for defining onset of late menopausal transition (Harlow, et al, 2006; Randolph, et al, 2006; Harlow, et al., Under review). WHAT S NEXT? After 16 years, SMWHS is coming to a close. As of January 1, only Ellen Mitchell, Nancy Woods and Kathy Smith-DiJulio will remain to write the final report, finish writing papers and close the offices. You can imagine all the data that has to be stored! After June 1, Ellen Mitchell will be the only person maintaining the study and contacting you. Her goal is to support your participation in the study until you have reached 5 years after your final menstrual period. As seen in the Table on the first page, 64 women are continuing in the study. During this time Ellen s focus will be on what happens in terms of symptoms during the early postmenopausal period. Not much is known about this particular phase in the reproductive lives of women so thank you to all of you for continuing to participate and provide data that will help fill existing gaps in knowledge. This research has been funded by the following federal grants: National Institute of Nursing Research (NINR) R01-NR04141; NINR P30 NR04001, and the National Institute for Environmental Health Studies (NIEHS) ES-07-33.

PUBLICATIONS TO DATE Woods, N.F., Mitchell, E.S., Tao, E.Y., Viernes, H-M. A., Stapleton, P.L. and Farin, F.M., Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during menopausal transition: observations from the Seattle Midlife Women s Health Study, submitted to Menopause, The Journal the North American Menopause Society, (2006) Vol.13 (6), pages 902-910. Woods, N.F., Mariella, A., and Mitchell, E.S., Depressed mood symptoms during the menopausal transition: observations from the Seattle Midlife Women s Health Study, Climacteric, (2006) Vol. 9 (3), pages 195-203. Woods, N.F., Carr, M.C., Tao, E.Y., Taylor, H.J., Mitchell, E.S., Increased urinary cortisol during the menopausal transition, Menopause, the Journal the North American Menopause Society, (2006) Vol. 13 (2), pages 212-221. Woods, N.F. and Mitchell, E.S., Symptoms during the perimenopause: prevalence, severity, trajectory and significance in women s lives, The American Journal of Medicine, (2005) Vol. 118, 145-245. Smith-DiJulio, K., Mitchell, E.S. and Woods, N.F., Concordance of retrospective and prospective reporting of menstrual irregularity by women in the menopausal transition, Climacteric, (2005), Vol. 8, 390-397. Smith-DiJulio, K., Mitchell, E.S., & Woods, N. F. (2005). Influences on Decisions to Use Hormone Replacement Therapy. Communicating Nursing Research Conference Proceedings, (2005) Vol 38:121. Woods, N.F. and Mitchell, E.S., Perimenopause: An update. In Woods, N.F. and Heitkemper, M. (eds.) Nursing Clinics of North America: Women s Health, (2004) Vol. 39, Philadelphia, Elsevier Saunders, pp. 117-129. Mitchell, E.S., Woods, N.F., and Mariella, A.M., FSH and estrone patterns during the menopausal transition. Communicating Nursing Research Conference Proceedings (2003) Vol.36, 181. Mariella, A.M., Mitchell, E.S. and Woods, N.F. Depression in midlife women: what have we learned from longitudinal studies? International Congress Series, (2002) Vol. 1229, 39-43. Mitchell, E.S. and Woods, N.F., Midlife women s attributions about perceived memory changes: observations from the Seattle Midlife Women s Health Study, Journal of Women s Health and Gender Based Medicine, (2001) Vol. 10, 351-361. Mitchell, E.S., Woods, N.F. and Mariella, A., Three stages of menopausal transition from the Seattle Midlife Women s Health Study: toward a more precise definition, Menopause, The Journal of the North American Menopause Society, (2000) Vol. 7 (5), pp. 334-349.

Woods, N.F., Mitchell, E.S. and Adams, C., Memory functioning among midlife women: Observations from the Seattle Midlife Women s Health Study, Menopause, The Journal of the North American Menopause Society (2000), Vol. 7 (4), pp. 257-265. Woods, N.F. and Mitchell, E.S., Anticipating menopause: observations from the Seattle Midlife Women s Health Study, Menopause, The Journal of the American Menopause Society, (1999), Vol. 6 (2), pp. 167-173. Woods, N. F. and Mitchell, E.S., Women s images of midlife: observations from the Seattle Midlife Women s Health Study, Health Care for Women International, (1997) Vol. 18, 439-453. Mitchell, E. S. and Woods, N.F., Symptom experiences of midlife women: observations from the Seattle Midlife Women s Health Study, Maturitas, Journal of the Climacteric and Postmenopause, (1996) Vol. 25, 1-10. Woods, N.F. and Mitchell, E.S., Patterns of depressed mood in midlife women: observations from the Seattle Midlife Women s Health Study, Research in Nursing & Health, (1996), Vol. 19, 111-123. Manuscripts Under Review Woods, N.F., Smith-DiJulio, K., Percival, D.B., Tao, E.Y., Taylor, H.J., and Mitchell, E. S. Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women s Health Study, Journal of Women s Health. Mitchell, E.S., Farin, F.M., Stapleton, P.L., Tao, E.Y., Smith-DiJulio, K. and Woods, N.F. Genetic influences on age at menarche, age at final menstrual period and stages of the menopausal transition: From the Seattle Midlife Women s Health Study, Menopause, The Journal of the North American Menopause Society. Manuscripts In Progress Woods, N.F., Mitchell, E.S., Percival, D.P., Tao, E.Y. and Smith-DiJulio, K. Depressed mood across the menopausal transition and early postmenopause. Woods, N.F., Smith-DiJulio, Percival, D.P., and Mitchell, E.S. Stress and stress arousal across the menopausal transition and early postmenopause. Mitchell, E.S., Woods, N.F., Smith-DiJulio, K., Tao, E.Y., Percival, D.P. Patterns of change in menstrual bleeding across the menopausal transition.

Smith-DiJulio, K., Mitchell, E.S., Percial, D.P., Tao, E.Y., and Woods, N.F. Hot flash severity in hormone therapy users and nonusers across the menopausal transition and early postmenopause. Tao, E.Y., Mitchell, E.S., Smith-DiJulio, K., Percival, D.P., Woods, N.F. Risk factors for selfreported premenstrual syndrome. Woods, N.F., Smith-DiJulio, K., Mitchell, E.S. and Percival, D.P. Sexuality and the menopausal transition.